Recombinant <i>Helicobacter pylori</i> Vaccine Delivery Vehicle: A Promising Tool to Treat Infections and Combat Antimicrobial Resistance

• Main Authors: Yakhya Dieye (Author), Cheikh Momar Nguer (Author), Fatou Thiam (Author), Abou Abdallah Malick Diouara (Author), Cheikh Fall (Author)
• Format: Book
• Published: MDPI AG, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Antimicrobial resistance (AMR) has become a global public health threat. Experts agree that unless proper actions are taken, the number of deaths due to AMR will increase. Many strategies are being pursued to tackle AMR, one of the most important being the development of efficient vaccines. Similar to other bacterial pathogens, AMR in <i>Helicobacter pylori</i> (<i>Hp</i>) is rising worldwide. <i>Hp</i> infects half of the human population and its prevalence ranges from <10% in developed countries to up to 90% in low-income countries. Currently, there is no vaccine available for <i>Hp</i>. This review provides a brief summary of the use of antibiotic-based treatment for <i>Hp</i> infection and its related AMR problems together with a brief description of the status of vaccine development for <i>Hp</i>. It is mainly dedicated to genetic tools and strategies that can be used to develop an oral recombinant <i>Hp</i> vaccine delivery platform that is (i) completely attenuated, (ii) can survive, synthesize in situ and deliver antigens, DNA vaccines, and adjuvants to antigen-presenting cells at the gastric mucosa, and (iii) possibly activate desired compartments of the gut-associated mucosal immune system. Recombinant <i>Hp</i> vaccine delivery vehicles can be used for therapeutic or prophylactic vaccination for <i>Hp</i> and other microbial pathogens.

Item Description

10.3390/antibiotics11121701
2079-6382